Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
Division of Rheumatology, Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico.
RMD Open. 2024 Nov 20;10(4):e004833. doi: 10.1136/rmdopen-2024-004833.
The 2019 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria score (≥20 points) has been associated with poor outcomes. We aimed to evaluate its utility as a predictor for mortality and hospitalisation and to derive and validate an ominosity score based on the SLE classification criteria set.
Incident patients with SLE in a population-based cohort were included. The association between the 2019 EULAR/ACR SLE score and mortality and hospitalisation was assessed using Cox regression adjusted for age, sex and calendar year. An ominosity score for mortality was developed based on the SLE criteria set. The least absolute shrinkage and selection operator method was used to estimate model coefficients. Concordance and calibration were assessed by cross-validation and by plotting the observed event rates against the deciles of predicted probabilities.
Among 374 patients with incident SLE, a EULAR/ACR score ≥20 points was not associated with an increased risk of mortality (HR 1.17, 95% CI 0.67 to 2.03) or first hospitalisation (HR 1.14, 95% CI 0.79 to 1.64) compared with a score ≤19 points. The derived ominosity score for mortality included age, sex, thrombocytopaenia, neuropsychiatric manifestations, subacute cutaneous or discoid lupus, non-scarring alopecia, inflammatory arthritis, renal involvement, antiphospholipid antibodies and hypocomplementaemia. This model demonstrated a concordance=0.76 with adequate calibration. Age and sex were the main predictors, as seen in the model including just age, sex and year (concordance=0.77).
The 2019 EULAR/ACR SLE criteria score was not associated with mortality and hospitalisation. The derived ominosity score for mortality presented good prediction for mortality but was not better than age and sex alone.
2019 年欧洲抗风湿病联盟(EULAR)/美国风湿病学会(ACR)系统性红斑狼疮(SLE)分类标准评分(≥20 分)与不良结局相关。我们旨在评估其作为死亡率和住院的预测因子的效用,并基于 SLE 分类标准集推导和验证一个预后评分。
在一项基于人群的队列中纳入了新诊断的 SLE 患者。使用 Cox 回归调整年龄、性别和日历年来评估 2019 年 EULAR/ACR SLE 评分与死亡率和住院之间的关系。根据 SLE 标准集开发了一个用于死亡率的预后评分。使用最小绝对收缩和选择算子方法估计模型系数。通过交叉验证和绘制观察到的事件发生率与预测概率的十分位数来评估一致性和校准。
在 374 名新诊断的 SLE 患者中,与评分≤19 分相比,EULAR/ACR 评分≥20 分与死亡率(HR 1.17,95%CI 0.67 至 2.03)或首次住院(HR 1.14,95%CI 0.79 至 1.64)的风险增加无关。用于死亡率的预后评分包括年龄、性别、血小板减少症、神经精神表现、亚急性皮肤或盘状狼疮、非瘢痕性脱发、炎症性关节炎、肾脏受累、抗磷脂抗体和低补体血症。该模型的一致性为 0.76,校准良好。年龄和性别是主要的预测因素,就像只包括年龄、性别和年份的模型一样(一致性为 0.77)。
2019 年 EULAR/ACR SLE 标准评分与死亡率和住院无关。用于死亡率的预后评分对死亡率有较好的预测作用,但并不优于年龄和性别单独使用。